A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.

Whatever specific shape work takes in the near and distant future, it’s likely the COVID-19 era will be looked back upon as a before-and-after dividing line.

"Small quality differentials combined with large price differentials suggests that health systems have not, on average, realized their potential for better care at equal or lower cost," Harvard researchers found. 

A new study published in JACC: Heart Failure offers more evidence that a patient's feelings can strongly influence their risk of poor cardiovascular health. 

Results demonstrate how implementing adjusted procedures to limit radiation exposures for children may lower cancer risks and save on health care costs.

Prenatal MRI is adept at revealing potentially damaging placental lesions affecting fetuses whose mothers were infected with COVID-19 while carrying.

The move could reclaim overpayments of an estimated $479 million from 2018 and $4.7 billion over 10 years.

The FDA has cleared U.K.-based Adaptix to market a 3D X-ray system that, according to the company, images hands, feet and elbows “at a fraction of the radiation dose and per-study cost of traditional CT.”